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Background: In Australia, “continued dispensing” (CD) is a new model for supply of pre-
scription medications. Under specific circumstances, community pharmacists are allowed to 
dispense a further one month supply of prescription only medications without a valid prescrip-
tion. It allows continuation and treatment adherence when patients run out of statin and/or oral 
contraceptive (OC) medications, when it is not practical or they fail to plan accordingly to get 
a new prescription. 
Objective: The aim of this study was to explore patient attitudes towards a CD model, including 
any perceived concerns or associated risks with CD prior to its introduction.
Methods: An Australia-wide computer-assisted telephone interview survey of statin and OC 
users aged 18 years or older was conducted in July 2013 prior to implementation of the CD 
model. A telephone number list was generated via a random number generation function based 
on a broad breakdown of the Australian population as outlined in the June 2013 Australian 
Bureau of Statistics data. The sample target for the survey was 300, consisting of 150 statin 
users and 150 OC users.
Results: There were a total of 301 respondents, comprising 151 statin users and 150 OC users. 
Approximately 37% of all respondents had experienced running out of their medications in the 
past 12 months, of whom 35.4% had temporarily stopped treatment and 33.6% requested their 
medication from a pharmacist without a valid prescription. OC users were more likely to run 
out of their medications (P=0.021). The majority of respondents had a regular pharmacy (86%) 
and therefore would be eligible for CD in the future. The majority of those surveyed had no 
concerns about CD or perceived it as posing no risks. Concerns raised included consultation 
privacy and the pharmacist’s lack of access to their medical records.
Conclusion: Australian users of statin and OC medications showed a high level of support for 
CD. Given that a significant proportion of patients temporarily stopped treatment when they 
ran out of medications and had no valid prescription, implementation of CD may alleviate the 
negative consequences of therapy interruption in statin and OC users in the short term. Longer-
term solutions and opportunities to expand CD require further exploration. 
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Introduction
Continued dispensing (CD) is a new supply model for certain prescription only 
medications in Australia when patients run out of their prescriptions. According to 
Medicare Australia, the CD initiative “will allow pharmacists to supply eligible PBS 
[Pharmaceutical Benefit Scheme] medicines to a customer when there is an immediate 
need for the medicine, but it is not practical for the customer to get a prescription”.1 
As part of the Australian government’s broader National Medicines Policy, the 
PBS provides timely, reliable, and affordable access to necessary medicines for 
Australians. In regards to CD, oral contraceptive (OC) and lipid-modifying agents, 
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namely statins, are the only medication classes that can be 
dispensed according to current CD guidelines. 
The usual practice for chronic disease prescribing in 
Australia is that the doctor writes a prescription for the 
medication for one month supply and issues up to five 
repeats to cover up to a 6-month period.2 For patients meet-
ing specific criteria, up to 11 repeats can be prescribed and 
therefore cover the patient for one year.3 However, there 
are circumstances where patients run out of their medica-
tions before the next appointment.4 As a result, they may 
need to ask the pharmacist to provide a supply without a 
prescription.5,6 The current system allows pharmacists to 
dispense under the provisions of Emergency Supply, Owing 
Prescription, or the recently introduced CD.7 The Emergency 
Supply system involves dispensing without a prescription 
and prior contact with the prescriber; however, its main 
drawbacks are the limited quantity of medication that may 
be dispensed (namely 3 days’ supply), out of pocket expense 
to the patient, and medication wastage in the pharmacy as 
a result of broken packs.8 The Owing Prescription model 
requires prior authorization by the prescriber before dispens-
ing and the prescriber should send the new prescription to 
the pharmacy within 7 days. The prescription is used to 
claim reimbursement for the medication from Medicare 
Australia through the PBS system.9 This overcomes the 
abovementioned disadvantages of the Emergency Supply 
system, but prior contact with the prescriber is not always 
possible or practical, and it has the potential for unpaid 
efforts on the part of doctors and pharmacists during the 
process of following up prescriptions. The CD model has 
been implemented to provide pharmacists with an additional 
option to ensure treatment continuation, and in doing so to 
overcome the practical drawbacks of the Emergency Supply 
and Owing Prescription systems.8 
CD does not require prior authorization by the prescriber 
or the need to obtain a prescription, and there is no extra 
cost to the patient or medication wastage. In addition, the 
quantity dispensed under CD is one standard pack of the 
medication which is usually enough for one month, allow-
ing adequate time for the patient to obtain an appointment 
with their doctor, thus avoiding potential nonadherence due 
to therapy interruption.8
CD aims to prevent patient medication nonadherence 
as it allows continuity of treatment when patients do not 
have a prescription. Patients would prefer availability of 
medications without prescription if they were easily acces-
sible, reduced the need to visit their doctors and achieved 
at a lower cost.10,11 Therefore, easier access to medications, 
without a  prescription or an extra cost (which CD provides) 
are encouraging factors to enhance patient adherence.12 
On the other hand, patients’ lack of awareness and 
acceptance, pharmacists’ unwillingness to participate, and 
doctors’ attitudes towards CD may have negative impacts on 
CD implementation. Pharmacists have reported low levels 
of patient awareness of new services provided in community 
pharmacies.13,14 Prior to the implementation of CD in Aus-
tralia, the Australian Medical Association15 declared that it 
was “strongly opposed to pharmacists dispensing prescription 
medication without a valid prescription and without reference 
to the patient’s treating medical practitioner”. 
 As patient attitudes towards obtaining medication through 
the CD provisions have not been previously researched, this 
study aimed to explore their attitudes towards CD, including 
any perceived concerns and/or risks related to CD prior to 
its implementation in Australia.
Patients and methods
This study was approved by the human research ethics com-
mittee of Curtin University (approval number PH-06-13). 
Data were collected by a telemarketing company, CDM 
Direct Communication Services, using computer-assisted 
telephone interview (CATI). This method was chosen as it 
has the advantages of time and cost saving, and is practical 
when taking into the account the geographical expanse of 
Australia.16 It also allows respondents to ask the interviewer 
questions if clarification is needed. Additionally, the ques-
tionnaire usually takes less time and has been reported to be 
more enjoyable to answer when compared with those that 
are self-administered.17,18 
A telephone number list was generated via a random 
number generation function based on a broad breakdown 
of the Australian population as outlined in the June 2013 
Australian Bureau of Statistics data. Telephoning was car-
ried out via random digit dialing within each state. The final 
target list generated had a total of 25,000 records. Telephon-
ing was carried out by staff members of the telemarketing 
company who were not part of the study, therefore mini-
mizing potential bias. This sample allowed for a prevalence 
estimation of ±5%. In addition to being either a statin user or 
an OC user, the respondent had to be 18 years or older and 
English-speaking. Respondents who used both medications 
were interviewed as OC users. Eligible candidates were told 
that the interview would take about 15 minutes and were 
considered consented if they answered yes to: “Would you 
like to participate in this interview?” If the person appeared 
to need assistance, then another household member was 
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allowed to assist the respondent. Respondents were also 
offered to be called at another time if the first call timing 
was not convenient, and they could withdraw at any time 
during the interview. The study was conducted in July 2013, 
before the actual start of the CD supply method in Australia 
(September 2013). Therefore, respondents’ views were not 
affected by any positive or negative experience with CD, 
thus minimizing study bias.19,20 
Questionnaire design 
Data were collected using a questionnaire consisting of 
38 questions. A literature review and experience from a 
previous study16 assisted in developing the questionnaire. 
It was validated by staff members within the pharmacy 
practice group at Curtin University and by the telemarketing 
company group.
The questionnaire contained three parts: part 1, which 
collected demographic information; part 2, which collected 
basic information about other disease(s) and medication, and 
part 3, which focused on patients’ perceptions of concerns 
and risks associated with CD, their thoughts on maximum 
number of CD utilizations in a 12-month period, and 
whether other medications should be included within the CD 
provisions. A five-point Likert scale was used to measure 
respondents’ attitudes towards the questions in part 3 of the 
questionnaire. This paper focuses on patients’ perceptions of 
perceived risks and concerns with CD, and the relationship 
between the two.
Data analysis
Answers through the option “Other please specify” were 
translated verbatim and thematically analyzed. The statisti-
cal analysis for closed-ended questions was undertaken in 
three steps using Statistical Package for the Social Sciences 
version 22 software (IBM Corp., Armonk, NY, USA). Step 1 
was a descriptive analysis and was carried out to describe the 
distribution of the answers. Step 2 included assessment of 
respondents’ overall support of CD. The study participants 
were not asked directly if they supported CD; instead they 
were asked two questions, namely, if they perceived CD 
as a source of any concerns and risks. For the purpose of 
analysis, the respondents were divided into three groups: 
those who perceived CD as a source of either concerns or 
risks (group A), those who perceived CD as a source of both 
concerns and risks (group B), and those who did not perceive 
CD as a source of either concerns or risk (group C, ie, fully 
 supportive). Step 3 aimed to determine if there were any 
statistically significant associations between concern and 
risk perceptions. In contrast with the null hypothesis, the 
alternative hypothesis assumed that participants’ percep-
tions of concerns were affected by their perception of risks. 
Therefore, the binary logistic regression test was used to 
predict the association between perceptions of concern and 




A total of 10,479 calls were made, from which there were 
3,460 successful connections; of these, there were 716 out-
right refusals to participate, with a further 297 calls truncated 
early as the respondents were deemed incapable of complet-
ing the survey. Of the remaining 2,447 respondents, 2,146 
were deemed ineligible, leaving a sample of 301 comprising 
151 statin users and 150 OC users.
The respondents were predominantly female (80%; 
n=241). Just over half of respondents (51.5%; n=155) were 
60 years of age or younger. Almost half of the respondents 
(50.5%) were from the state of New South Wales (Figure 1), 
and the majority lived in metropolitan areas (84%; n=256). 
Disease and medication data 
Atorvastatin (eg, Lipitor®) was the most commonly used 
statin (37.7%; n=57) followed by rosuvastatin (Crestor®); 
26.5%; n=40), then simvastatin (eg, Zocor®); 15.8%; n=24). 
Ethinylestradiol 30 µg + levonorgestrel 150 µg (Levlen® or 
Monofeme®) was the most frequently used contraceptive agent 
(38.6%; n=58) followed by ethinylestradiol 30/40/30 µg + 
levonorgestrel 50/75/125 µg (Trifeme®, Triphasil®, or 
Triquilar®) which was used by 12.6% (n=19) of OC users. 
Of the respondents, over a third reported having at least one 
other disease (38.5%; n=116, see Table 1). 
Medication supply history
One hundred and ten (36.5%) of the respondents had run out of 
either their statin or OC in the previous 12 months (Table 1), 
of whom 35.4% reported that they temporarily stopped the 
medication until they could see their doctor, while 33.6% 
sought an extra supply from their pharmacists until they 
could see their doctor. 
regular pharmacy 
The majority of the respondents (86%; n=259) reported 
having a regular pharmacy (Table 1). However, this differed 
amongst OC users and statin users (74.9% versus 97.4%, 
respectively; P0.0001).





Perceived concerns and risks  
related to cD
The questionnaire was designed to explore patients’ con-
cerns about CD and whether they thought it would be safe 
to obtain their medication through CD. In order to simplify 
and explain CD to the participants, CD was presented in the 
questionnaires as obtaining one additional supply from the 
pharmacist when the patient ran out of medication and it was 
not practical to see the doctor.
When patients obtain medication through CD, they 
need to discuss their health issues with the pharmacist, and 
answer a range of questions in order for the pharmacist to 
determine whether CD is appropriate and safe. The major-
ity of the respondents were not concerned with the planned 
CD initiative (89.4%; n=269), mainly because they trusted 
their pharmacist’s judgment in determining if it would be 
appropriate for them (72.8%; n=219). Other reasons given 
in support of CD were “the pharmacist will refer me to the 

















Table 1 respondents’ characteristics
Characteristic Responses Number Percentage
had other medical conditions no 60.8 183
Yes 38.5 116
Prefer not to disclose 0.7 2.0
Approximate number of occasions in past 12 months when  





Prefer not to disclose 3 1.0
if impractical to see usual doctor, action taken by  
respondents to acquire further medication supply
nil, stop treatment 40 35.4
Ask pharmacist 37 33.6
see after hours doctor 8 7.1
see another doctor 17 15.0
Borrow 4 3.5
Other 5 4.4
Prefer not to disclose 1 0.9
regular customer of a pharmacy no 42 14.0
Yes 259 86.0
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doctor if needed”, “pharmacists are easier to access than 
doctors”, “it will save my time”, and “it allows me not to 
miss any doses of my medicine” (Table 2). 
respondents’ perception of concerns  
and risk 
Amongst the 30 respondents who expressed concerns regard-
ing CD, the main issues raised related to consultation privacy 
and pharmacists’ lack of access to their medical records. 
Some respondents stated they would prefer to see their doctor 
(n=4), lacked confidence in the pharmacist’s capabilities or 
training (n=4), or saw CD as a way patients might abuse medi-
cations (n=1). The majority of respondents (88.7%; n=267) 
did not see any risk associated with the CD process. 
estimation of cD support
As outlined in the Methods section, support for CD was 
assessed on the basis of the combined responses of respon-
dents to Q16 (Perceived concerns in discussing health issues 
with the pharmacist as part of CD) and Q20 (Perceived 
risks from pharmacists providing an additional supply of 
medication without a valid prescription). Respondents were 
deemed to be fully supportive of CD if they disagreed about 
any concerns or risks associated with CD (Figure 2). Two 
hundred and forty-nine respondents (82.7%) disagreed with 
both questions (ie, those in group C, no concerns and no risk) 
whilst eight (2.6%) agreed with both questions (ie, those in 
group B, both concern and risk). These results indicated a 
high level of support for CD by potential users.
relationship between perceptions  
of concerns and risks 
Binary logistic regression analysis was used to examine if 
participants’ perceptions of concerns were affected by their 
perception of risks. The null hypothesis assumed no such 
Table 2 respondents’ perceptions of concern and risk 
Question Response Number Percentage
Do you have any concerns regards cD? no 269 89.4
Yes 30 10.0
Prefer not to disclose 2 0.7
reasons for lack of concern Pharmacists know if it is safe or not to take an  
additional supply when i run out of my medication
219 72.8
The pharmacist will refer me to the doctor if needed 177 58.8
Pharmacists are easier to access than doctors 171 57
reduce work load of my doctor 141 47.2
it saves my time 167 55.5
it makes me not miss any dose of my medicine 160 53.2
All of the above 147 48.8
Other 19 6.3
Prefer not to disclose 4 1.3
reasons for concern lack of privacy in the pharmacy 6 20
Pharmacist has no access to my health records 10 33.3
All of the above 6 20
Other 8 26.7
Prefer not to disclose 1 0.3
Do you believe cD poses any risk? no 267 88.7
Yes 15 5.0
Prefer not to disclose 19 6.3
Abbreviation: cD, continued dispensing.
Figure 2 Proportion of respondents (n=301) who fully supported continued 
dispensing (ie, disagreed with both Q16 and Q20). 
Notes: Q16, Perceived concerns to discuss health issues with the pharmacist when 
providing an additional supply; and Q20, Perceived risks for pharmacists providing 
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relationship. This analysis revealed a highly statistically 
significant association between respondents’ perceptions 
of concerns (independent variable) and perceptions of 
risks (dependent variable; P0.0001). “Disagreed” was 
the reference group. The odds ratio was 16.7, meaning 
that concerned respondents were 16.7 times more likely 
than unconcerned respondents to agree that there would 
be risk associated with CD. This suggests that participants 
who were concerned may be so because they thought CD 
is potentially risky.
Discussion
This study explored attitudes of statin users and OC users 
towards CD. It was conducted almost 2 months before the 
actual implementation of CD in Australia in September 2013, 
hence the results represent respondents’ attitudes before any 
positive or negative experiences with CD which may have 
influenced their views.20–22 
In the present study, the vast majority of the respondents 
strongly supported CD, and did not see it as a source of any 
concerns or risks. The potential explanations for this may 
be related to consumers’ trust in pharmacists assuming 
additional responsibilities and/or related to the nature of CD 
itself. Pharmacy consumers’ trust of pharmacists assuming 
new roles has been reported previously in the Australian 
literature.16 In the present study, almost three quarters of 
respondents selected “Pharmacists know if it is safe or not 
to take an additional supply” option. Further, they thought 
that their “Pharmacist would refer them to the doctor when 
it is needed”, which is consistent with previous findings.23,24 
Additionally, CD reserves the diagnosis to doctors, with 
pharmacists able to continue the treatment until patients can 
see their doctors. In previous studies16,25 of attitudes towards 
expanded pharmacists’ roles, the majority of respondents 
(patients and pharmacists) strongly supported expanding the 
role of pharmacists to prescribe medications for diseases that 
were previously diagnosed by doctors (supplementary pre-
scribing) rather than pharmacist diagnosing and prescribing 
(independent pharmacist prescribing). This is in contrast with 
the negative attitude of doctors towards CD as reported by the 
Australian Medical Association prior to its implementation.15 
The Australian Medical Association described CD as an 
unsafe process. Whilst recognizing that not all respondents 
may have been qualified to estimate any risk associated with 
CD, all were chronic medication users and the majority did 
not see it as a risky method for obtaining their medications 
in the short term. This may be due to their long-term use of 
medication and prior experience with pharmacists positively 
influencing their views. 
As a method of medication supply, CD was instigated 
to minimize patient nonadherence with their medications, 
particularly as a result of treatment interruption, which 
occurs when patients run out of medication before they are 
able to obtain a new prescription. Although more than half 
of the respondents reported never being in this situation, 
a significant proportion had (~37%), and of these, over a 
third temporarily stopped treatment until they saw their 
doctor. Temporary discontinuation of a medication may 
have negative health outcomes;12 further, it may lead to 
permanent treatment cessation.26 Discontinuation of statins 
has been reported as a source of concern to doctors and 
pharmacists.24,27 Significant statin discontinuation rates have 
been reported, especially amongst younger patients and 
asymptomatic cases.28,29 In the case of OC users, Rosenberg 
and Waugh30 reported that 80% who stopped using their 
OCs either adopted another less effective method of contra-
ception or completely discontinued, even though they were 
still at risk of unwanted pregnancy. In an Australian study,31 
approximately 90% of pregnancies amongst women aged 
under 18 years were unintended and 80% amongst those 
aged 18–24 years. In the present study, OC users, who are 
younger than their statin counterparts, reported running out 
of their medication more often than statin users (P=0.021). 
In the case of statins, other studies have shown older users 
report being more adherent than younger users.28,29 
Approximately one third of respondents who experienced 
running out of their medications had requested an additional 
supply from a pharmacist. Before implementation of CD in 
Australia, pharmacists had only two options if they were to 
grant such requests, ie, Emergency Supply or Owing Pre-
scription. Both options have their disadvantages. Issues with 
the first include increased out of pocket expense for patients 
and wastage for pharmacies from open packs. Emmerton et al 
reported that the additional medication cost may deter some 
patients from purchasing medications under Emergency 
Supply.11 The other method, Owing Prescription, represents 
an administrative burden and involves unpaid effort for both 
doctors and pharmacists. In order to assist patients to obtain 
their medications at a lower cost, a pharmacist may supply a 
full pack of the medication and then follow up with their doc-
tor to obtain a new prescription.88 This “in advance supply”, 
ie, before a prescription is issued, is generally restricted for 
regular pharmacy customers only, where a dual trust exists 
between the pharmacist and the patient. 
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Statin users were less likely to run out of medications 
than OC users (P=0.021). There are a number of possible 
reasons for this significant difference. Firstly, statin users 
were older, being more likely to be aged 60 years or over 
(P0.0001). It has been reported that those who are older 
are likely to be more adherent to their medications.29 Sec-
ondly, statin users are more likely to have other diseases 
and use more medications (P0.0001), so may have more 
regular contact with their doctors.28 Thirdly, statin users 
were more likely to have a regular pharmacy than OC users 
(97% versus 75%, P0.0001), and this would lead statin 
users to interact more with their pharmacists and be more 
likely to ask them for an additional supply if they ran out 
between doctors’ appointments. In addition, pharmacists 
would empathically dispense when they have the medication 
history of the patient, which is most likely to be available 
for regular customers.32,33 Finally, OC users were more 
likely to have full-time jobs (P0.0001) when compared 
with statin users, so may have more difficulty in organiz-
ing a doctor’s appointment.34 Moreover, OC users have the 
option of considering alternative contraceptive methods if 
they run out of OCs.30 
Among those who had run out of medication, less than a 
quarter reported seeing another doctor or an after hours doctor 
(~15% and ~7%, respectively). The more common actions 
were to stop treatment until they saw their regular doctor 
or ask for an additional supply from the pharmacist (~36% 
and ~33%, respectively). This indicates that patients are not 
in favor of changing their doctor to another doctor. This is 
consistent with a study of asthmatic patients that reported 
patients becoming less adherent to their medications if they 
received care from colleagues of their doctor.35 
Patient acceptance of any new service is conditioned 
by how they perceive it. Minimizing the risk of treatment 
interruption, hence nonadherence, is the ultimate goal of 
CD, which enables more convenient access to medications. 
Since pharmacists are more accessible than doctors,21 CD 
seems to have the capacity to gain client support. This 
is confirmed by the results of our study, where 57% of 
respondents agreed with “Pharmacies are easier to access 
than doctors”. Additionally, there were other reasons that 
were reported by some respondents, including trusting the 
pharmacist, pharmacy keeping records of dispensing, and 
being a regular customer and having a personal relationship 
with the pharmacist. On the other hand, lack of privacy 
and pharmacists having no access to medical records or 
both were identified by the small number of respondents 
concerned about CD. From a pharmacy perspective, 
inability to check medication histories for nonregular 
customers has been cited as a deterrent to more positive 
interactions,33 whilst customers’ personal experiences and 
perceptions, positive or negative, about pharmacists may 
strongly affect their attitudes towards pharmacists’ current 
and future roles.21 
The limitations of this study are acknowledged. This 
study was conducted via landline telephone which may 
limit the representation of individuals who only use mobile 
phones, especially younger individuals.36 In addition, 
some population groups were not included, ie, those who 
could not speak English and those aged under 18 years, 
acknowledging that Australia is a multicultural country37 
and OCs can be prescribed to teenagers younger than 
18 years.38 Finally, the plan was to obtain a stratified sample 
of consumers according to the population distribution in 
Australia, but this was not achieved. The main factors 
potentially contributing to this were the high number of 
nonconnections, consumers’ preference to participate, and 
project budget and time constraints, which may limit the 
generalizability of this study. 
Future work should explore the attitudes of statin 
users and OC users who have experienced CD to find out 
if their experience with CD has had positive or negative 
effects on their perceptions of CD. At the same time, 
the experiences and views of community pharmacists 
need to be gathered to assess whether they believe CD 
is an ideal solution to deal with patients who run out of 
their regular medications. Further areas of research may 
include the attitudes of patients with other chronic disease 
diseases regarding inclusion of their medications in the 
CD provisions.
Conclusion
Australian users of statin and OC medications showed a high 
level of support for CD. Given that a significant proportion 
of patients temporarily stop treatment when they run out of 
medications and have no valid prescription, CD may alleviate 
the negative consequences of therapy interruption in statin 
users and OC users in the short term. Strategies addressing 
the issue of supply beyond the one month allowable and the 
currently listed therapeutic groups of medications covered 
under CD need further exploration. 
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